Clinical trial evaluates blood stem cell transplantation for patients with T-cell disorders

stem cell transplant

Stem cell transplant
Photo courtesy of NCI Visuals Online

Patients with disorders of T-cell proliferation and/or dysregulation may be eligible to participate in a new clinical trial at the NIH Clinical Center.

All types of blood cells develop from hematopoietic (blood-forming) stem cells in bone marrow. T cells, a type of white blood cell, develop from stem cells and mature in the thymus gland. They play a key role in human immunity by protecting the body from infection and may also help to fight cancer. People whose T cells fail to properly develop or function can develop imbalances in the immune system that lead to cancer, autoimmune disease and other problems. Jennifer Kanakry, M.D., of the Experimental Transplantation and Immunology Branch is leading a study that transplants allogeneic blood-forming stem cells from healthy donors into patients with T-cell disorders. Although transplant may cure patients with these T-cell problems, these patients may be at higher risk for transplant rejection as a result of their underlying T-cell problem. The aim of this study is to use a novel approach to transplant to see if this risk of rejecting the transplant can be overcome so that patients can hopefully overcome their T-cell problem through the successful transplantation of a healthy, new immune system. identifier: NCT03663933
NCI Protocol ID: NCI-18-C-0135
Official Title: Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care.  Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.   

For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.

Summary Posted: Mon, 10/01/2018